Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 102,059 | 85,768 | 132,944 | 391,651 | 159,868 |
| Marketable Securities | 449,922 | 543,586 | 614,818 | 497,024 | 382,927 |
| Receivables | 70,523 | 42,991 | 40,445 | 31,164 | 37,207 |
| Inventories | 28,256 | 26,616 | 26,766 | 21,849 | 21,079 |
| TOTAL | $702,137 | $766,336 | $883,899 | $1,012,668 | $678,542 |
| Non-Current Assets | |||||
| PPE Net | 288,990 | 277,873 | 259,726 | 234,614 | 207,381 |
| Investments And Advances | 71,829 | 90,410 | 148,970 | 121,349 | 178,713 |
| Intangibles | 202,643 | 203,577 | 204,511 | 202,807 | 203,602 |
| Other Non-Current Assets | 45,711 | 45,208 | 48,338 | 47,036 | 52,389 |
| TOTAL | $609,173 | $617,068 | $661,545 | $605,806 | $642,085 |
| Total Assets | $1,311,310 | $1,383,404 | $1,545,444 | $1,618,474 | $1,320,627 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 42,115 | 58,981 | 43,274 | 23,533 | 34,213 |
| Accrued Expenses | 167,656 | 144,404 | 204,678 | 189,051 | 170,355 |
| Other current liabilities | 23,724 | 3,533 | 1,479 | 2,958 | 4,437 |
| TOTAL | $244,379 | $218,179 | $261,210 | $227,361 | $220,636 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 906,234 | 913,077 | 900,073 | 888,978 | 388,612 |
| TOTAL | $937,901 | $944,744 | $931,740 | $922,284 | $421,918 |
| Total Liabilities | $1,182,280 | $1,162,923 | $1,192,950 | $1,149,645 | $642,554 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 71,489 | 70,814 | 70,217 | 70,106 | 70,037 |
| Common Shares | 71 | 71 | 70 | 70 | 70 |
| Retained earnings | -3,104,822 | -2,944,994 | -2,781,022 | -2,629,189 | -2,384,083 |
| Other shareholders' equity | -3,098 | -3,967 | -6,573 | -10,222 | -8,914 |
| TOTAL | $129,030 | $220,481 | $352,494 | $468,829 | $678,073 |
| Total Liabilities And Equity | $1,311,310 | $1,383,404 | $1,545,444 | $1,618,474 | $1,320,627 |